What About Immunotherapy?



You’ve probably heard it already – it’s the new frontier.

Immunotherapy – there are many different medications under the umbrella of immunotherapy.  Of course, in prostate cancer, we have PROVENGE, but the next generation of immunotherapy, I think, will move the needle a lot more.

In addition, we are using other immunotherapy medications in our practice (currently used as off-label use for prostate cancer) such as YERVOY, OPDIVO, and KEYTRUDA.

These medication are really exciting and are changing the natural history of some of these very deadly cancers – into long-term remission.  For example in metastatic cancers – lung, melanoma, colon, head, neck, kidney – immunotherapy has been proven to prolong survival in all the cancers mentioned above.

I think, in the next 2-4 years, we will get some pretty good data for prostate cancer as well.  In prostate cancer, there are some early studies that look very promising, but we definitely need more data.  If I were to venture to take a guess, 1 in 5 men with prostate cancer will have a really good response to immunotherapy.  In addition, maybe another 30-40% men who take immunotherapy, their prostate cancer may even stabilize for a period of time.

*below information for provenge+Atezolizumab  clinical trial at Prostate Oncology Specialists > you may be eligible to participate as a patient, contact us > mail@prostateoncology.com

ROSSER 2015-4:  Phase Ib Study Assessing Different Sequencing Regimens of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer.

The purpose of the study is to compare the safety and tolerability of sequential atezolizumab followed by sipuleucel-T (Arm 1) vs. sipuleucel-T followed by atezolizumab (Arm 2) in patients who have asymptomatic or minimally symptomatic metastatic CRPC, not previously treated with docetaxel or cabazitaxel. https://clinicaltrials.gov/ct2/show/NCT03024216

Leave a Reply

Your email address will not be published. Required fields are marked *